These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 18941747

  • 1. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
    Shin BS, Kim HJ, Hong SH, Lee JB, Hwang SW, Lee MH, Yoo SD.
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):87-94. PubMed ID: 18941747
    [Abstract] [Full Text] [Related]

  • 2. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens J, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
    [Abstract] [Full Text] [Related]

  • 3. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 4. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
    Choi BC, Choi JS, Han HK.
    Int J Pharm; 2006 Oct 12; 323(1-2):81-5. PubMed ID: 16806758
    [Abstract] [Full Text] [Related]

  • 5. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.
    Cancer Res; 1996 May 01; 56(9):2112-5. PubMed ID: 8616858
    [Abstract] [Full Text] [Related]

  • 6. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges.
    Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R.
    Drug Deliv; 2010 Aug 01; 17(6):419-25. PubMed ID: 20429848
    [Abstract] [Full Text] [Related]

  • 7. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
    Hosten B, Abbara C, Petit B, Dauvin A, Bourasset F, Farinotti R, Gonin P, Bonhomme-Faivre L.
    Drug Metab Dispos; 2008 Aug 01; 36(8):1729-35. PubMed ID: 18508881
    [Abstract] [Full Text] [Related]

  • 8. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
    van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH.
    Clin Cancer Res; 1998 Oct 01; 4(10):2293-7. PubMed ID: 9796957
    [Abstract] [Full Text] [Related]

  • 9. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
    Innocenti F, Danesi R, Di Paolo A, Agen C, Nardini D, Bocci G, Del Tacca M.
    Drug Metab Dispos; 1995 Jul 01; 23(7):713-7. PubMed ID: 7587959
    [Abstract] [Full Text] [Related]

  • 10. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O.
    Clin Cancer Res; 2000 Nov 01; 6(11):4416-21. PubMed ID: 11106262
    [Abstract] [Full Text] [Related]

  • 11. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies.
    Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R.
    Eur J Pharm Biopharm; 2009 Feb 01; 71(2):310-7. PubMed ID: 18793723
    [Abstract] [Full Text] [Related]

  • 12. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL, Long ME, Bradshaw EL, Merz AL, Kerzic PJ.
    Cancer Chemother Pharmacol; 2005 Sep 01; 56(3):248-54. PubMed ID: 15856231
    [Abstract] [Full Text] [Related]

  • 13. Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process.
    Park JH, Chi SC, Lee WS, Lee WM, Koo YB, Yong CS, Choi HG, Woo JS.
    Arch Pharm Res; 2009 Jan 01; 32(1):139-48. PubMed ID: 19183887
    [Abstract] [Full Text] [Related]

  • 14. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
    Danhier F, Magotteaux N, Ucakar B, Lecouturier N, Brewster M, Préat V.
    Eur J Pharm Biopharm; 2009 Oct 01; 73(2):230-8. PubMed ID: 19577643
    [Abstract] [Full Text] [Related]

  • 15. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
    Park JH, Park JH, Hur HJ, Woo JS, Lee HJ.
    Eur J Pharm Sci; 2012 Feb 14; 45(3):296-301. PubMed ID: 22172604
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Jan 14; 59(1):43-50. PubMed ID: 16680462
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.
    Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP.
    Pharm Res; 2006 Jun 14; 23(6):1243-50. PubMed ID: 16715372
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.